Illumina (NASDAQ:ILMN) Price Target Raised to $184.00 at Stephens

Illumina (NASDAQ:ILMN) had its price objective raised by Stephens from $170.00 to $184.00 in a research report released on Tuesday,Benzinga reports. The brokerage currently has an overweight rating on the life sciences company’s stock.

ILMN has been the subject of a number of other research reports. Canaccord Genuity Group boosted their price target on shares of Illumina from $130.00 to $145.00 and gave the stock a “hold” rating in a research note on Tuesday, November 5th. JPMorgan Chase & Co. upped their price objective on Illumina from $125.00 to $140.00 and gave the stock a “neutral” rating in a report on Tuesday, November 5th. HSBC raised Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective on the stock in a report on Thursday, October 17th. Leerink Partners increased their price target on shares of Illumina from $160.00 to $200.00 and gave the company an “outperform” rating in a research report on Thursday, October 17th. Finally, Argus upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $150.00 price objective for the company in a report on Wednesday, August 28th. One analyst has rated the stock with a sell rating, eight have given a hold rating, fourteen have given a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Illumina has a consensus rating of “Moderate Buy” and an average target price of $164.00.

Illumina Trading Down 2.6 %

ILMN stock opened at $147.62 on Tuesday. The stock has a 50-day simple moving average of $138.50 and a two-hundred day simple moving average of $123.77. Illumina has a twelve month low of $92.26 and a twelve month high of $156.66. The company has a quick ratio of 1.85, a current ratio of 2.43 and a debt-to-equity ratio of 0.94.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Monday, November 4th. The life sciences company reported $1.14 EPS for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The company had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the previous year, the company earned $0.33 earnings per share. Illumina’s revenue for the quarter was down 3.5% on a year-over-year basis. As a group, sell-side analysts predict that Illumina will post 4.11 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ILMN. Primecap Management Co. CA increased its position in shares of Illumina by 462.5% during the second quarter. Primecap Management Co. CA now owns 2,428,760 shares of the life sciences company’s stock valued at $253,514,000 after buying an additional 1,997,010 shares during the period. Millennium Management LLC boosted its position in Illumina by 305.0% during the 2nd quarter. Millennium Management LLC now owns 1,485,599 shares of the life sciences company’s stock valued at $155,067,000 after acquiring an additional 1,118,747 shares in the last quarter. Capital World Investors grew its holdings in shares of Illumina by 41.1% during the 1st quarter. Capital World Investors now owns 2,753,504 shares of the life sciences company’s stock worth $378,111,000 after acquiring an additional 801,814 shares during the period. Marshall Wace LLP bought a new position in shares of Illumina in the 2nd quarter worth approximately $77,628,000. Finally, Swedbank AB purchased a new position in shares of Illumina in the 1st quarter valued at approximately $99,682,000. 89.42% of the stock is currently owned by institutional investors.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.